Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections

Ophthalmology

Volumn 119, Issue 2, 2012, Pages 321-326

  Hoang, Quan V ^a,b,c,d   Mendonca, Luis S ^a,b   Della Torre, Kara E ^a,b,d   Jung, Jesse J ^d   Tsuang, Angela J ^d   Freund, K Bailey ^a,b,c,d  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

^c New York Presbyterian Hospital   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; ODDS RATIO; RETREATMENT; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84856539469     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.08.011     Document Type: Article

References (21)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
3. H. Hollands, J. Wong, R. Bruen Short-term intraocular pressure changes after intravitreal injection of bevacizumab Can J Ophthalmol 42 2007 807 811
4. J.E. Kim, A.V. Mantravadi, E.Y. Hur, D.J. Covert Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents Am J Ophthalmol 146 2008 930 934
5. G. Mojica, S.M. Hariprasad, R.D. Jager, W.F. Mieler Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration [letter] Br J Ophthalmol 92 2008 584 (Pubitemid 351498004)
6. S.J. Bakri, J.S. Pulido, C.A. McCannel Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab Eye (Lond) 23 2009 181 185
7. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816 (Pubitemid 40051904)
8. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials Ophthalmology 113 2006 992 1001
9. T.J. Good, A.E. Kimura, N. Mandava, M.Y. Kahook Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents Br J Ophthalmol 95 2011 1111 1114
10. S.J. Bakri, C.A. McCannel, A.O. Edwards, D.M. Moshfeghi Persistent ocular hypertension following intravitreal ranibizumab Graefes Arch Clin Exp Ophthalmol 246 2008 955 958
11. M.Y. Kahook, A.E. Kimura, L.J. Wong Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections Ophthalmic Surg Lasers Imaging 40 2009 293 295
12. R.A. Adelman, Q. Zheng, H.R. Mayer Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections J Ocul Pharmacol Ther 26 2010 105 110
13. J.J. Tseng, S.K. Vance, K.E. Della Torre Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration J Glaucoma 2011 Mar 16 [Epub ahead of print]
14. M. Engelbert, S.A. Zweifel, K.B. Freund "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation Retina 29 2009 1424 1431
15. R.D. Jager, L.P. Aiello, S.C. Patel, E.T. Cunningham Jr Risks of intravitreous injection: a comprehensive review Retina 24 2004 676 698 (Pubitemid 39391758)
16. D.Y. Choi, M.C. Ortube, C.A. McCannel Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib Retina 31 2011 1028 1035
17. M. Kernt, U. Welge-Lssen, A. Yu Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells [in German] Ophthalmologe 104 2007 965 971
18. J.G. Ladas, F. Yu, R. Loo Relationship between aqueous humor protein level and outflow facility in patients with uveitis Invest Ophthalmol Vis Sci 42 2001 2584 2588 (Pubitemid 32954867)
19. M. Georgopoulos, K. Polak, F. Prager Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin) Br J Ophthalmol 93 2009 457 462
20. M. Sniegowski, N. Mandava, M.Y. Kahook Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis Open Ophthalmol J [serial online] 4 2010 28 29 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944993/?tool=pubmed Accessed July 24, 2011
21. L. Liu, D.A. Ammar, L. Ross Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling Invest Ophthalmol Vis Sci 52 2011 1023 1034